Compare Eli Lilly And Co (LLY) vs Xylem, Inc. (XYL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Xylem, Inc. — how do they compare? Eli Lilly And Co trades at $1,178.99 (market cap $1.04T), while Xylem, Inc. trades at $102.9 (market cap $23.81B). The key difference: Eli Lilly And Co is far larger — about 43.7× Xylem, Inc.'s market cap, and Xylem, Inc. pays the higher dividend (1.69%). Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Xylem, Inc. for 50 Days on average.
| LLY | XYL | |
|---|---|---|
Market Cap | $1.04T | $23.81B |
Volume | 3,064,878 | 2,234,713 |
Sector | Health | Industrials |
52-Week High | $1.28K | $152.95 |
52-Week Low | $799.57 | $100.92 |
Typical Hold Time | 93 Days | 50 Days |
Enterprise Value | $1.09T | $25.59B |
Dividend Yield | 0.59% | 1.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,176.69, down 1.01% on the day, amid a bullish technical outlook and strong fundamental performance. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 consensus. Revenue surged to $65.18B in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing growth prospects.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include elevated valuation multiples and competitive pressures in the pharmaceutical sector. With a consensus price target of $1,350, upside potential exists, but investors should weigh execution risks against the company's innovation pipeline.
Xylem (XYL) trades at $102.20, up 0.36% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q3 2026 results due October 27, 2026. Revenue grew to $9.04B in 2025, with a net income margin of 10.59%, while recent acquisitions like Cornell Pump and Roper Pump aim to strengthen its industrial water solutions presence.
The outlook is supported by steady revenue growth and margin expansion, but risks include China weakness and higher debt from recent note offerings. Analyst consensus is mixed with a $149.13 price target, suggesting potential upside, though technical indicators caution near-term pressure. Investment appeal hinges on execution of growth strategies amid competitive and macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Xylem, Inc.
Xylem is a global leader in water technology and offers a wide range of solutions, including the transport, treatment, testing, and efficient use of water for customers in the utility, industrial, commercial, and residential sectors. Xylem was spun off from ITT in 2011. Based in Rye Brook, New York, Xylem has a presence in over 150 countries and employs 16,200. The company generated $6.2 billion in revenue and $611 million in adjusted operating income in 2021.
Read more on XYL →
